vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and WillScot Holdings Corp (WSC). Click either name above to swap in a different company.
WillScot Holdings Corp is the larger business by last-quarter revenue ($566.0M vs $339.0M, roughly 1.7× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs -33.1%, a 46.3% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (-2.7% vs -6.1%). WillScot Holdings Corp produced more free cash flow last quarter ($149.7M vs $87.2M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -1.8%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
WillScot Holdings Corp is a leading provider of modular space solutions and portable storage services across North America. It serves a wide range of sectors including construction, commercial development, education, healthcare, government projects, and special events, offering flexible, scalable temporary and semi-permanent space solutions tailored to diverse client needs.
HAE vs WSC — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $566.0M |
| Net Profit | $44.7M | $-187.3M |
| Gross Margin | 59.7% | 50.4% |
| Operating Margin | 19.9% | -32.5% |
| Net Margin | 13.2% | -33.1% |
| Revenue YoY | -2.7% | -6.1% |
| Net Profit YoY | 19.3% | -310.0% |
| EPS (diluted) | $0.95 | $-1.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $566.0M | ||
| Q3 25 | $327.3M | $566.8M | ||
| Q2 25 | $321.4M | $589.1M | ||
| Q1 25 | $330.6M | $559.6M | ||
| Q4 24 | $348.5M | $602.5M | ||
| Q3 24 | $345.5M | $601.4M | ||
| Q2 24 | $336.2M | $604.6M | ||
| Q1 24 | — | $587.2M |
| Q4 25 | $44.7M | $-187.3M | ||
| Q3 25 | $38.7M | $43.3M | ||
| Q2 25 | $34.0M | $47.9M | ||
| Q1 25 | $58.0M | $43.1M | ||
| Q4 24 | $37.5M | $89.2M | ||
| Q3 24 | $33.8M | $-70.5M | ||
| Q2 24 | $38.4M | $-46.9M | ||
| Q1 24 | — | $56.2M |
| Q4 25 | 59.7% | 50.4% | ||
| Q3 25 | 59.5% | 49.7% | ||
| Q2 25 | 59.8% | 50.3% | ||
| Q1 25 | 58.4% | 53.7% | ||
| Q4 24 | 55.5% | 55.8% | ||
| Q3 24 | 54.2% | 53.5% | ||
| Q2 24 | 52.0% | 54.1% | ||
| Q1 24 | — | 54.0% |
| Q4 25 | 19.9% | -32.5% | ||
| Q3 25 | 17.9% | 21.0% | ||
| Q2 25 | 16.8% | 21.5% | ||
| Q1 25 | 21.6% | 21.3% | ||
| Q4 24 | 16.9% | 28.9% | ||
| Q3 24 | 15.0% | -5.9% | ||
| Q2 24 | 11.8% | -0.9% | ||
| Q1 24 | — | 22.1% |
| Q4 25 | 13.2% | -33.1% | ||
| Q3 25 | 11.8% | 7.6% | ||
| Q2 25 | 10.6% | 8.1% | ||
| Q1 25 | 17.5% | 7.7% | ||
| Q4 24 | 10.8% | 14.8% | ||
| Q3 24 | 9.8% | -11.7% | ||
| Q2 24 | 11.4% | -7.7% | ||
| Q1 24 | — | 9.6% |
| Q4 25 | $0.95 | $-1.02 | ||
| Q3 25 | $0.81 | $0.24 | ||
| Q2 25 | $0.70 | $0.26 | ||
| Q1 25 | $1.17 | $0.23 | ||
| Q4 24 | $0.74 | $0.48 | ||
| Q3 24 | $0.66 | $-0.37 | ||
| Q2 24 | $0.74 | $-0.25 | ||
| Q1 24 | — | $0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $14.6M |
| Total DebtLower is stronger | $1.2B | $3.6B |
| Stockholders' EquityBook value | $911.5M | $856.3M |
| Total Assets | $2.5B | $5.8B |
| Debt / EquityLower = less leverage | 1.34× | 4.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $14.6M | ||
| Q3 25 | $296.4M | $14.8M | ||
| Q2 25 | $292.9M | $12.8M | ||
| Q1 25 | $306.8M | $10.7M | ||
| Q4 24 | $320.8M | $9.0M | ||
| Q3 24 | $299.3M | $11.0M | ||
| Q2 24 | $344.4M | $5.9M | ||
| Q1 24 | — | $13.1M |
| Q4 25 | $1.2B | $3.6B | ||
| Q3 25 | $1.2B | $3.6B | ||
| Q2 25 | $1.2B | $3.7B | ||
| Q1 25 | $1.2B | $3.6B | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | $3.6B | ||
| Q2 24 | — | $3.5B | ||
| Q1 24 | — | $3.5B |
| Q4 25 | $911.5M | $856.3M | ||
| Q3 25 | $849.2M | $1.1B | ||
| Q2 25 | $882.3M | $1.0B | ||
| Q1 25 | $820.8M | $1.0B | ||
| Q4 24 | $906.9M | $1.0B | ||
| Q3 24 | $878.9M | $1.1B | ||
| Q2 24 | $905.4M | $1.2B | ||
| Q1 24 | — | $1.3B |
| Q4 25 | $2.5B | $5.8B | ||
| Q3 25 | $2.4B | $6.1B | ||
| Q2 25 | $2.5B | $6.1B | ||
| Q1 25 | $2.5B | $6.0B | ||
| Q4 24 | $2.5B | $6.0B | ||
| Q3 24 | $2.5B | $6.0B | ||
| Q2 24 | $2.5B | $6.0B | ||
| Q1 24 | — | $6.2B |
| Q4 25 | 1.34× | 4.15× | ||
| Q3 25 | 1.44× | 3.39× | ||
| Q2 25 | 1.39× | 3.55× | ||
| Q1 25 | 1.49× | 3.56× | ||
| Q4 24 | — | 3.62× | ||
| Q3 24 | — | 3.42× | ||
| Q2 24 | — | 2.88× | ||
| Q1 24 | — | 2.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $158.9M |
| Free Cash FlowOCF − Capex | $87.2M | $149.7M |
| FCF MarginFCF / Revenue | 25.7% | 26.5% |
| Capex IntensityCapex / Revenue | 1.9% | 1.6% |
| Cash ConversionOCF / Net Profit | 2.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $737.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $158.9M | ||
| Q3 25 | $111.3M | $191.2M | ||
| Q2 25 | $17.4M | $205.3M | ||
| Q1 25 | $116.6M | $206.6M | ||
| Q4 24 | $43.8M | $178.9M | ||
| Q3 24 | $48.8M | $-1.6M | ||
| Q2 24 | $-27.4M | $175.6M | ||
| Q1 24 | — | $208.7M |
| Q4 25 | $87.2M | $149.7M | ||
| Q3 25 | $106.3M | $186.9M | ||
| Q2 25 | $13.6M | $199.0M | ||
| Q1 25 | $100.9M | $202.0M | ||
| Q4 24 | $35.2M | $176.6M | ||
| Q3 24 | $39.4M | $-4.9M | ||
| Q2 24 | $-33.1M | $169.4M | ||
| Q1 24 | — | $202.1M |
| Q4 25 | 25.7% | 26.5% | ||
| Q3 25 | 32.5% | 33.0% | ||
| Q2 25 | 4.2% | 33.8% | ||
| Q1 25 | 30.5% | 36.1% | ||
| Q4 24 | 10.1% | 29.3% | ||
| Q3 24 | 11.4% | -0.8% | ||
| Q2 24 | -9.8% | 28.0% | ||
| Q1 24 | — | 34.4% |
| Q4 25 | 1.9% | 1.6% | ||
| Q3 25 | 1.5% | 0.7% | ||
| Q2 25 | 1.2% | 1.1% | ||
| Q1 25 | 4.7% | 0.8% | ||
| Q4 24 | 2.5% | 0.4% | ||
| Q3 24 | 2.7% | 0.6% | ||
| Q2 24 | 1.7% | 1.0% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | 2.09× | — | ||
| Q3 25 | 2.88× | 4.41× | ||
| Q2 25 | 0.51× | 4.28× | ||
| Q1 25 | 2.01× | 4.80× | ||
| Q4 24 | 1.17× | 2.01× | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | -0.71× | — | ||
| Q1 24 | — | 3.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
WSC
| Modular Space Leasing | $249.8M | 44% |
| Value Added Product And Services | $101.0M | 18% |
| Portable Storage Leasing | $83.0M | 15% |
| Delivery Revenue | $48.2M | 9% |
| Installation Revenue | $45.0M | 8% |
| Rental Units | $19.7M | 3% |
| New Units | $15.5M | 3% |
| Value Added Services | $10.3M | 2% |
| Other Leasing Related Products And Services | $3.8M | 1% |
